LAUSR

1789 One area of focus is developing a multimodality approach that combines systemic therapy and surgery to cure more men with a new diagnosis of localized high-risk prostate cancer, as there is a suboptimal cure rate with standard therapy.2 To this end, Dr Taplin led a series of investigator-initiated trials in localized high-risk prostate cancer that assessed various combinations and durations of next-generation hormone therapies with prostatectomy.3 On the basis of the positive results of these trials, she is currently leading a phase 3 trial assessing the effects of apalutamide and leuprolide on patients with prostate cancer before and after prostatectomy. “If this trial is successful, it will prove that early pathology outcomes are a surrogate for late radiographic outcomes and allow quicker therapy development in patients with localized high-risk prostate cancer,” says Dr Taplin.